Scholar Rock Holding Corp
Company Profile
Business description
Scholar Rock Holding Corp is a biopharmaceutical company focused on improving the lives of children and adults with Spinal Muscular Atrophy and other rare, severe, and debilitating neuromuscular diseases. Its pipeline candidates include apitegromab and a subcutaneous formulation of apitegromab. The clinical-stage pipeline also includes SRK-439, an investigational subcutaneously administered fully human anti-pro/latent myostatin antibody with high inhibitory potency and selectivity toward myostatin, being developed for the treatment of rare neuromuscular diseases. The company also maintains early-stage programs focused on therapies for rare, severe, and debilitating neuromuscular diseases.
Contact
301 Binney Street
3rd Floor
CambridgeMA02142
USAT: +1 857 259-3860
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
289
Stocks News & Analysis
stocks
Chart of the Week: ASX retail offers pockets of value in softening conditions
stocks
ASX tech share upgraded following AI contract wins
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,799.10 | 170.10 | -1.90% |
| CAC 40 | 7,964.51 | 71.36 | -0.89% |
| DAX 40 | 25,199.19 | 200.02 | -0.79% |
| Dow JONES (US) | 50,906.05 | 443.87 | -0.86% |
| FTSE 100 | 10,606.00 | 30.71 | -0.29% |
| HKSE | 24,613.27 | 89.70 | 0.37% |
| NASDAQ | 26,861.06 | 63.52 | 0.24% |
| Nikkei 225 | 68,560.96 | 1,807.24 | 2.71% |
| NZX 50 Index | 13,810.51 | 23.88 | -0.17% |
| S&P 500 | 7,651.54 | 19.30 | -0.25% |
| S&P/ASX 200 | 8,619.10 | 170.20 | -1.94% |
| SSE Composite Index | 3,842.19 | 11.74 | 0.31% |